Table 2.
Outcome in Relatives | AML(n = 20,579) | Controls(n = 90,406) | RR | 95% CI | MDS(n = 3,994) | Controls(n = 15,818) | RR | 95% CI |
---|---|---|---|---|---|---|---|---|
Myeloid | ||||||||
AML | 15 | 70 | 0.9 | 0.5 to 1.9 | 3 | 11 | 1.1 | 0.30 to 3.8 |
MDS | 4 | 10 | 1.8 | 0.6 to 5.7 | 2 | 2 | 4.0 | 0.4 to 43.1 |
AML/MDS | 19 | 80 | 1.0 | 0.6 to 1.9 | 5 | 13 | 1.5 | 0.5 to 4.8 |
CML | 9 | 29 | 1.3 | 0.6 to 2.9 | 1 | 2 | 2.0 | 0.2 to 21.6 |
Any myeloid malignancy* | 28 | 109 | 1.1 | 0.7 to 1.8 | 6 | 15 | 1.6 | 0.6 to 4.5 |
PV | 13 | 25 | 2.3 | 1.2 to 4.5 | 1 | 5 | 0.8 | 0.1 to 6.7 |
ET | 5 | 22 | 1.0 | 0.4 to 2.6 | 0 | 3 | ||
MF | 4 | 17 | 1.0 | 0.4 to 3.1 | 1 | 3 | 1.3 | 0.1 to 12.6 |
MPD NOS | 3 | 12 | 1.1 | 0.3 to 3.9 | 2 | 0 | ||
Any myeloproliferative malignancy† | 25 | 75 | 1.5 | 0.9 to 2.3 | 4 | 10 | 1.6 | 0.50 to 5.0 |
Any myeloid or myeloproliferative malignancy | 53 | 182 | 1.3 | 0.9 to 1.8 | 10 | 24 | 1.6 | 0.7 to 3.6 |
Lymphoid | ||||||||
NHL | 67 | 287 | 1.0 | 0.8 to 1.3 | 8 | 46 | 0.7 | 0.3 to 1.4 |
CLL | 25 | 70 | 1.6 | 1.0 to 2.5 | 2 | 16 | 0.5 | 0.1 to 2.1 |
HL | 20 | 64 | 1.3 | 0.8 to 2.2 | 2 | 10 | 0.8 | 0.2 to 3.6 |
MM | 26 | 117 | 1.0 | 0.6 to 1.5 | 4 | 23 | 0.7 | 0.2 to 2.0 |
Any lymphoproliferative malignancy | 140 | 539 | 1.1 | 0.9 to 1.4 | 16 | 95 | 0.7 | 0.4 to 1.1 |
ALL | 7 | 26 | 1.2 | 0.5 to 2.7 | 1 | 2 | 2.0 | 0.2 to 21.3 |
Any hematologic malignancy | 197 | 742 | 1.2 | 1.0 to 1.4 | 27 | 120 | 0.9 | 0.6 to 1.3 |
Any solid tumor | 2,087 | 8,476 | 1.1 | 1.0 to 1.1 | 381 | 1,412 | 1.1 | 1.0 to 1.2 |
NOTE. Bolded entries indicate that risk ratio (RR) is significantly different from 1.0.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ET, essential thrombocythemia; HL, Hodgkin's lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL, non-Hodgkin's lymphoma; NOS, not otherwise specified; PV, polycythemia vera.
Any myeloid malignancy includes AML, MDS, and CML.
Any myeloproliferative malignancy includes PV, ET, MF, and MPD NOS.
Any lymphoproliferative malignancy includes NHL, HL, CLL, and MM.